^
Association details:
| Biomarker: | ALK A348D |
|---|---|
| Cancer: | Leukemia |
| Drug: | Alunbrig (brigatinib) (EGFR inhibitor, ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Therapeutically targetable ALK mutations in leukemia
Excerpt:
Treatment of ALK mutant-transformed Ba/F3 cells with AP26113 potently inhibited cell growth with an IC50 of 3 nM for the A348D mutant and 0.6 nM for the F856S mutant.
DOI:
https://dx.doi.org/10.1158%2F0008-5472.CAN-14-1576
